Latest stories on ACRV
Acrivon Therapeutics acquires ACR-525 program from Aqilion
The Fly64 · neutralm&a
Acrivon Therapeutics, Inc. (ACRV) files 8-K
SEC 8-K50 · neutralgeneral
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Business Insider56 · neutralproduct/pr
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
GlobeNewswire64 · neutralproduct/pr
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Business Insider64 · neutralproduct/pr
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
StockTitan56 · neutralgeneral
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Business Insider56 · neutralgeneral
Acrivon Therapeutics GAAP EPS of -$0.43 beats by $0.07
Seeking Alpha56 · neutralearnings
Acrivon Therapeutics, Inc. (ACRV) files 8-K
SEC 8-K50 · neutralgeneral
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
GlobeNewswire56 · neutralearnings
Acrivon Therapeutics: Priced For Failure, Built For Precision
Seeking Alpha58 · neutralgeneral
Acrivon Therapeutics, Inc. (ACRV) files 8-K
SEC 8-K50 · neutralgeneral
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit | ACRV Stock News
StockTitan56 · neutralproduct/pr
ACRV: [Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity
StockTitan SEC50 · neutralgeneral
Acrivon Therapeutics GAAP EPS of -$0.49 beats by $0.03
Seeking Alpha56 · neutralearnings